Category Archives: Value Health

Patient Versus General Population Health State Valuations: A Case Study Of Low Back Pain.

Related Articles

Patient Versus General Population Health State Valuations: A Case Study Of Low Back Pain.

Value Health. 2015 Nov;18(7):A686

Authors: van Dongen…

Continue reading

Posted in Value Health | Tagged | Leave a comment

Evaluation of The Cost Effectiveness of Rifaximin-Á In The Reduction of Recurrence of Overt Hepatic Encephalopathy In Belgium.

Related Articles

Evaluation of The Cost Effectiveness of Rifaximin-Á In The Reduction of Recurrence of Overt Hepatic Encephalopathy In Belgium.

Value Health. 2015…

Continue reading

Posted in Value Health | Tagged | Leave a comment

Patient Heterogeneity In Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease (Copd): are Current Models Suitable to Evaluate Personalized Medicine.

Related Articles

Patient Heterogeneity In Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease (Copd): are Current Models Suitable to Evaluate Personalized Medicine. …

Continue reading

Posted in Value Health | Tagged | Leave a comment

Operational Validation of Health Economic Decision Analytic Models.

Related Articles

Operational Validation of Health Economic Decision Analytic Models.

Value Health. 2015 Nov;18(7):A706

Authors: Corro Ramos I, Al MJ, Vemer P,…

Continue reading

Posted in Value Health | Tagged | Leave a comment

Assessment of Validation of Health-Economics Decision Models In Intervention Studies of Seasonal Influenza and Breast Cancer.

Related Articles

Assessment of Validation of Health-Economics Decision Models In Intervention Studies of Seasonal Influenza and Breast Cancer.

Value Health. 2015…

Continue reading

Posted in Value Health | Tagged | Leave a comment

New Standards to Derive Preference-Based Hrqol Values.

Related Articles

New Standards to Derive Preference-Based Hrqol Values.

Value Health. 2015 Nov;18(7):A726

Authors: Krabbe PF

PMID: 26534069 [PubMed – in…

Continue reading

Posted in Value Health | Tagged | Leave a comment

Economic Impact of Treating Chinese Postmenopausal Women with 17-ß-Estradiol Combined Hormone Replacment Therapy (Hrt) Compared with the Alternative Practices.

Related Articles

Economic Impact of Treating Chinese Postmenopausal Women with 17-ß-Estradiol Combined Hormone Replacment Therapy (Hrt) Compared with the Alternative Practices.

Continue reading

Posted in Value Health | Tagged | Leave a comment

Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006-2013.

Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006-2013.

Value Health. 2015 Mar;18(2):284-91

Authors: Charokopou M, Majer IM, Raad Jd, Broekhuizen S, Postma M, Heeg B

Abstract
OBJECTIVES: To identify the factors that influence the Scottish Medicines Consortium (SMC) in deciding whether to accept pharmaceutical technologies for use within the Scottish health care system.
METHODS: A database of SMC submissions between 2006 and 2013 was created, containing a range of clinical, economic, and other factors extracted from published health technology assessment reports. A binomial outcome variable was used, defined as the decision to “accept for use” or “not recommend” a technology. Univariate and multivariate analyses were conducted to assess the impact by means of odds ratios (ORs) of the submitted evidence on the recommendation decision.
RESULTS: Out of 463 applications, 265 were accepted for use (57%) and 198 (43%) were not recommended for use within National Health Service Scotland. Univariate analyses showed that 13 variables significantly affected the SMC decision. Of these 13 variables, 7 variables were shown to have a meaningful impact in the multivariate analysis. Four of these concerned the outcome of cost-effectiveness analyses; the fact that a submission was supported by a cost-minimization analysis was the strongest positive variable (OR = 10.30) and a submission showing a product not being cost-effective (i.e., incremental cost-effectiveness ratio above £30,000/quality-adjusted life-year gained) was the strongest negative predictor (OR = 0.47). The other variables concerned whether the submission was related to a product indicated for a nervous system disease (OR = 0.41), whether it was indicated for nonchronic use (OR = 1.66), and whether the submission was performed by a big company (OR = 2.83).
CONCLUSIONS: This study demonstrated that the outcome of cost-effectiveness analyses is an important factor affecting the SMC’s reimbursement recommendation decision.

PMID: 25773564 [PubMed – in process]

Continue reading

Posted in Value Health | Leave a comment

Mapping the Clinical Chronic Obstructive Pulmonary Disease Questionnaire onto Generic Preference-Based EQ-5D Values.

Mapping the Clinical Chronic Obstructive Pulmonary Disease Questionnaire onto Generic Preference-Based EQ-5D Values.

Value Health. 2015 Mar;18(2):299-307

Authors: Boland MR, van Boven JF, Kocks JW, van der Molen T, Goossens LM, Chavannes NH, Rutten-van Mölken MP

Abstract
OBJECTIVES: To develop a model to predict EuroQol five-dimensional questionnaire (EQ-5D) values from clinical chronic obstructive pulmonary disease (COPD) questionnaire (CCQ) scores.
METHODS: We used data from three clinical trials (the Randomized Clinical Trial on Effectiveness of Integrated COPD Management in Primary Care [RECODE], the Assessment Of Going Home Under Early Assisted Discharge [GO-AHEAD], and the Health Status Guided COPD Care [MARCH]). Data were randomly split into an estimation sample and a validation sample. The conceptual similarity between patient-reported CCQ and preference-based EQ-5D scores was assessed using correlation and principal-component analysis. Different types of models were estimated with increasing complexity. We selected the final models on the basis of mean absolute error and root mean square error when comparing predicted and observed values from the same population (internal validity) and from different trial populations (external validity). We also developed models for different country-specific EQ-5D value sets.
RESULTS: The principal-component analysis showed that the CCQ domains functional state and mental state are associated with four dimensions of the EQ-5D. The EQ-5D dimension pain/discomfort formed a separate construct on which no CCQ item loaded. The mean observed EQ-5D values were not significantly different from the mean predicted EQ-5D values in internal validation samples but did significantly differ in external validation samples. The models underestimated EQ-5D values in milder health states and overestimated them in more severe health states. The predictive ability of the models was similar across different EQ-5D value sets.
CONCLUSIONS: The models can predict mean EQ-5D values that are similar to observed mean values in a similar population. The overestimating/underestimating of the low/high EQ-5D values, however, limits its use in Markov models. Therefore, mapping should be used cautiously.

PMID: 25773566 [PubMed – in process]

Continue reading

Posted in Value Health | Leave a comment

Risk attitudes and personality traits predict perceptions of benefits and risks for medicinal products: a field study of European medical assessors.

Risk attitudes and personality traits predict perceptions of benefits and risks for medicinal products: a field study of European medical assessors.
Value Health. 2015 Jan;18(1):91-9
Authors: Beyer AR, Fasolo B, de G… Continue reading

Posted in Value Health | Leave a comment

Evaluation of Patient Registries Supporting Reimbursement Decisions: The Case of Oxaliplatin for Treatment of Stage III Colon Cancer.

Evaluation of Patient Registries Supporting Reimbursement Decisions: The Case of Oxaliplatin for Treatment of Stage III Colon Cancer.
Value Health. 2015 Jan;18(1):84-90
Authors: Mohseninejad L, van Gils C, Uyl-de Gro… Continue reading

Posted in Value Health | Leave a comment

A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.

Related Articles

A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.

Value Health. 2014 Jun;17(4):445-53

Authors:…

Continue reading

Posted in Value Health | Tagged | Leave a comment

Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.

Related Articles

Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.

Value Health. 2014 Jul;17(5):525-36

Authors: Hoogendoorn M, Feenstra TL, Asukai Y, Borg S, Hansen RN, Jansson SA, Samyshkin Y, Wacker M, Briggs AH, Lloyd A, Sullivan SD, Rutten-van Mölken MP

Abstract
OBJECTIVES: To compare different chronic obstructive pulmonary disease (COPD) cost-effectiveness models with respect to structure and input parameters and to cross-validate the models by running the same hypothetical treatment scenarios.
METHODS: COPD modeling groups simulated four hypothetical interventions with their model and compared the results with a reference scenario of no intervention. The four interventions modeled assumed 1) 20% reduction in decline in lung function, 2) 25% reduction in exacerbation frequency, 3) 10% reduction in all-cause mortality, and 4) all these effects combined. The interventions were simulated for a 5-year and lifetime horizon with standardization, if possible, for sex, age, COPD severity, smoking status, exacerbation frequencies, mortality due to other causes, utilities, costs, and discount rates. Furthermore, uncertainty around the outcomes of intervention four was compared.
RESULTS: Seven out of nine contacted COPD modeling groups agreed to participate. The 5-year incremental cost-effectiveness ratios (ICERs) for the most comprehensive intervention, intervention four, was €17,000/quality-adjusted life-year (QALY) for two models, €25,000 to €28,000/QALY for three models, and €47,000/QALY for the remaining two models. Differences in the ICERs could mainly be explained by differences in input values for disease progression, exacerbation-related mortality, and all-cause mortality, with high input values resulting in low ICERs and vice versa. Lifetime results were mainly affected by the input values for mortality. The probability of intervention four to be cost-effective at a willingness-to-pay value of €50,000/QALY was 90% to 100% for five models and about 70% and 50% for the other two models, respectively.
CONCLUSIONS: Mortality was the most important factor determining the differences in cost-effectiveness outcomes between models.

PMID: 25128045 [PubMed – in process]

Continue reading

Posted in Value Health | Tagged , | Leave a comment

Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.

Related Articles

Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.

Value Health. 2014 Mar;17(2):223-30

Authors: de Vries FM, Denig P, Visser ST, Hak E, Postma MJ

Abstract
BACKGROUND: Statins are lipid-lowering drugs that reduce the risk of cardiovascular events in patients with diabetes.
OBJECTIVES: The objective of this study was to determine whether statin treatment for primary prevention in newly diagnosed type 2 diabetes is cost-effective, taking nonadherence, baseline risk, and age into account.
METHODS: A cost-effectiveness analysis was performed by using a Markov model with a time horizon of 10 years. The baseline 10-year cardiovascular risk was estimated in a Dutch population of primary prevention patients with newly diagnosed diabetes from the Groningen Initiative to Analyse Type 2 Diabetes Treatment (GIANTT) database, using the United Kingdom Prospective Diabetes Study risk engine. Statin adherence was measured as pill days covered in the IADB.nl pharmacy research database. Cost-effectiveness was measured in costs per quality-adjusted life-year (QALY) from the health care payers’ perspective.
RESULTS: For an average patient aged 60 years, the base case, statin treatment was highly cost-effective at €2245 per QALY. Favorable cost-effectiveness was robust in sensitivity analysis. Differences in age and 10-year cardiovascular risk showed large differences in cost-effectiveness from almost €100,000 per QALY to almost being cost saving. Treating all patients younger than 45 years at diabetes diagnosis was not cost-effective (weighted cost-effectiveness of almost €60,000 per QALY).
CONCLUSIONS: Despite the nonadherence levels observed in actual practice, statin treatment is cost-effective for primary prevention in patients newly diagnosed with type 2 diabetes. Because of large differences in cost-effectiveness according to different risk and age groups, the efficiency of the treatment could be increased by targeting patients with relatively higher cardiovascular risk and higher ages.

PMID: 24636380 [PubMed – indexed for MEDLINE]

Continue reading

Posted in Value Health | Tagged , | Leave a comment

Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force.

Related Articles
Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force.
Value Health. 2013 Sep-Oct;16(6):1106-7
Authors: Vemer P, Krabbe… Continue reading

Posted in Value Health | Tagged , | Leave a comment

Value of information analysis from a societal perspective: a case study in prevention of major depression.

Related Articles

Value of information analysis from a societal perspective: a case study in prevention of major depression.

Value Health. 2013 Jun;16(4):490-7

Authors: …

Continue reading

Posted in Value Health | Tagged | Leave a comment

Probability elicitation to inform early health economic evaluations of new medical technologies: a case study in heart failure disease management.

Related Articles

Probability elicitation to inform early health economic evaluations of new medical technologies: a case study in heart failure disease management.

Value Health….

Continue reading

Posted in Value Health | Tagged | Leave a comment

Evidence synthesis assumes additivity on the scale of measurement: response to “rank reversal in indirect comparisons” by norton et Al.

Related Articles
Evidence synthesis assumes additivity on the scale of measurement: response to “rank reversal in indirect comparisons” by norton et Al.
Value Health. 2013 Mar-Apr;16(2):449-51
Authors: van Valkenhoef G, Ades AE… Continue reading

Posted in Value Health | Tagged , | Leave a comment

On discounting of health gains from human papillomavirus vaccination: effects of different approaches.

Related Articles

On discounting of health gains from human papillomavirus vaccination: effects of different approaches.

Value Health. 2012 May;15(3):562-7

Authors: Westra…

Continue reading

Posted in Value Health | Tagged | Leave a comment

Practical implications of differential discounting of costs and health effects in cost-effectiveness analysis.

Practical implications of differential discounting of costs and health effects in cost-effectiveness analysis.

Value Health. 2011 Dec;14(8):1173-4

Authors: Westra TA, Parouty MB,…

Continue reading

Posted in Value Health | Tagged | Leave a comment